COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
暂无分享,去创建一个
[1] R. von Känel,et al. Associations of employment status with opioid misuse: Evidence from a nationally representative survey in the U.S. , 2022, Journal of psychiatric research.
[2] D. Barouch,et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.
[3] D. Angus,et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] N. Daneman,et al. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. , 2022, JAMA.
[5] W. Schaffner,et al. Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[6] D. Barouch,et al. Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, medRxiv.
[7] A. Monto,et al. Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study , 2022, medRxiv.
[8] S. Balter,et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[9] Yawen Jiang,et al. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China , 2022, Annals of Internal Medicine.
[10] D. Barouch,et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron , 2022, Nature.
[11] Karl A. Soetebier,et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[12] Manish M Patel,et al. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021 , 2022, MMWR. Morbidity and mortality weekly report.
[13] S. Schrag,et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.
[14] K. Bruxvoort,et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.
[15] T. Peto,et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants , 2022, The New England journal of medicine.
[16] S. E. Reese,et al. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021 , 2021, American Journal of Transplantation.
[17] K. Spiess,et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households , 2021, medRxiv.
[18] T. Ndung’u,et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.
[19] P. Maes,et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.
[20] J. Bhiman,et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.
[21] K. Mølbak,et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study , 2021, medRxiv.
[22] J. Mascola,et al. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.
[23] Liyuan Liu,et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.
[24] Katherine C DeRuff,et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak , 2021, Cell.
[25] S. Kissler,et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons , 2021, The New England journal of medicine.
[26] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[27] D. Follmann,et al. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge , 2021, The New England journal of medicine.
[28] L. Abu-Raddad,et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.
[29] N. Gupta,et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses , 2021, The Lancet Infectious Diseases.
[30] R. Lin,et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study , 2021, Clinical Microbiology and Infection.
[31] J. Salomon,et al. Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison , 2021, The New England journal of medicine.
[32] M. Yaghoubi,et al. Systematic review of productivity loss among healthcare workers due to Covid‐19 , 2021, The International journal of health planning and management.
[33] I. Diamond,et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.
[34] A. Nordström,et al. Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members , 2021, JAMA internal medicine.
[35] O. A. Ogun,et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.
[36] N. Ferguson,et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study , 2021, The Lancet Infectious Diseases.
[37] P. G. Choe,et al. Work Restrictions for Healthcare Personnel with Potential In-hospital Exposure to SARS-CoV-2: Experience at a Tertiary Hospital , 2021, Journal of Korean medical science.
[38] J. Tate,et al. Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[39] J. Mascola,et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase , 2021, The New England journal of medicine.
[40] Meei-Li W Huang,et al. Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants , 2021, medRxiv.
[41] K. Natarajan,et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[42] P. McKeigue,et al. Effect of Vaccination on Transmission of SARS-CoV-2 , 2021, The New England journal of medicine.
[43] A. Iwasaki,et al. Prevention of host-to-host transmission by SARS-CoV-2 vaccines , 2021, The Lancet Infectious Diseases.
[44] J. Starrfelt,et al. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[45] C. Longhurst,et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce , 2021, The New England journal of medicine.
[46] Kwok-Hung Chan,et al. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3 , 2021, Vaccines.
[47] R. Link-Gelles,et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[48] David W. McDonald,et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[49] B. O. Oude Munnink,et al. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers , 2021, medRxiv.
[50] C. Whaley,et al. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. , 2021, Health affairs.
[51] Y. Liu,et al. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.
[52] Catherine M. Brown,et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[53] M. Binnicker. Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus , 2021, Journal of clinical microbiology.
[54] H. D. de Melker,et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[55] M. Lipsitch,et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.
[56] Wildo Navegantes de Araújo,et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study , 2021, The Lancet Regional Health - Americas.
[57] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[58] S. Cauchemez,et al. Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study , 2021, medRxiv.
[59] Forrest W. Crawford,et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel , 2021, medRxiv.
[60] H. Schuitemaker,et al. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination , 2021, The New England journal of medicine.
[61] Lu Shi,et al. Negative Employment Changes During the COVID-19 Pandemic and Psychological Distress , 2021, Journal of occupational and environmental medicine.
[62] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.
[63] Ross J. Harris,et al. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England , 2021, The New England journal of medicine.
[64] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[65] P. Delafontaine,et al. Ct Values Do Not Predict Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students , 2021, The Journal of Molecular Diagnostics : JMD.
[66] Andrew L. Phillips,et al. Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines , 2021, medRxiv.
[67] A. Sheikh,et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.
[68] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[69] M. Hassany,et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.
[70] J. Guedj,et al. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness , 2021, medRxiv.
[71] Scott L. Bain,et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.
[72] D. Hatzigeorgiou,et al. Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness analysis , 2021, Journal of Hospital Infection.
[73] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[74] Andrew L. Phillips,et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[75] D. Bonsall,et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.
[76] Graham W. Taylor,et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.
[77] N. Shah,et al. Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[78] M. Ponga,et al. Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations , 2021, Scientific Reports.
[79] P. Gilbert,et al. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection , 2021, PLoS pathogens.
[80] M. Hernán,et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.
[81] A. Goyal,et al. Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events , 2021, eLife.
[82] Y. Kreiss,et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.
[83] A. Venkatakrishnan,et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system , 2021, medRxiv.
[84] Charles Y. Tan,et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.
[85] P. Dormitzer,et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.
[86] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[87] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.
[88] A. Pollard,et al. A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.
[89] H. Tani,et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients , 2020, PloS one.
[90] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[91] M. Cevik,et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis , 2020, The Lancet Microbe.
[92] Joel C. Miller,et al. Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control , 2020, PLoS biology.
[93] D. Ho,et al. Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies , 2020, PLoS biology.
[94] Rebecca J. Loomis,et al. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.
[95] Sebastian Funk,et al. Extended data: Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China , 2020 .
[96] Frank Grosveld,et al. A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.
[97] N. Guiso,et al. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines , 2014, Expert review of vaccines.
[98] P. Gilbert,et al. Sieve analysis in HIV-1 vaccine efficacy trials. , 2013, Current opinion in HIV and AIDS.
[99] M. Lipsitch,et al. Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.
[100] A. Zuckerman,et al. Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.
[101] R. Evans. European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).